March 31, 2017 - The court granted defendants' motion to dismiss.
April 14, 2016 - Defendants filed a motion to dismiss.

February 12, 2016 - The lead plaintiffs filed an amended complaint on behalf of investors who purchased Northwest Biotherapeutics Inc (NASDAQ: NWBO) common shares between January 13, 2014 and August 21, 2015. The lead plaintiffs allege that the defendants violated the Securities Exchange Act of 1934 by issuing false and misleading statements between January 13, 2014 and August 21, 2015.

December 14, 2015 - Lead plaintiffs and lead counsel were appointed.

October 26, 2015 - Lead plaintiff motions were filed.

August 26, 2015 - An investor in shares of Northwest Biotherapeutics Inc (NASDAQ: NWBO) filed a lawsuit in the U.S. District Court for the District of Maryland over alleged violations of Federal Securities Laws by Northwest Biotherapeutics Inc in connection with certain allegedly false and misleading statements made between March 8, 2013 and August 20, 2015.

According to the complaint the plaintiff alleges on behalf of purchasers of Northwest Biotherapeutics Inc (NASDAQ: NWBO) common shares between March 8, 2013 and August 20, 2015, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 8, 2013 and August 20, 2015 defendants made allegedly false and/or misleading statements and/or allegedly failed to disclose that Northwest Biotherapeutics Inc’s claims regarding positive results from its DCVax-Direct Trial were based on preliminary and unconfirmed trial results, that the DCVax-Direct Trial results on which Northwest Biotherapeutics Inc reported had not been reviewed or analyzed by the hospitals conducting the trials, that Northwest Biotherapeutics Inc’s statements about DCVax-Direct were derived from patient case report forms, which the hospitals were obliged to send to the Company only because it sponsored the study, that Northwest Biotherapeutics Inc was the subject of an aggressive stock promotion campaign which included promoters using fictitious identities and false credentials, that German regulators required additional information from Northwest Biotherapeutics Inc in order for its DCVax-L Trial to continue uninterrupted, and that as a result of the above, Northwest Biotherapeutics Inc’s financial statements were materially false and misleading at all relevant times.

Northwest Biotherapeutics Inc reported that its annual Total Revenue rose from $0.01 million in 2011 to $0.81 million in 2013. Shares of Northwest Biotherapeutics Inc (NASDAQ: NWBO) grew from $3.21 per share in November 2013 to as high as $9.18 per share in March 2014, respectively $8.97 per share on June 18, 2014.

Then on June 19, 2014, an article was published that stated that The prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics (NWBO) for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct.”

On July 7, 2014, a report published stated that Northwest Biotherapeutics Inc has been the subject of a massive promotional campaign which has seen the stock price soar. And, in some cases, authors have used fictitious identities and fake credentials within healthcare or finance. In fact they are simply paid writers. On this news, shares of Northwest Biotherapeutics Inc fell $0.52 per share to $6.62 in intraday trading on July 7, 2014.

On August 21, 2015, pre-market, news broke that Northwest Biotherapeutics Inc’s Phase 3 DCVax-L brain cancer treatment clinical trial in Germany was temporarily halted. A reason is yet to be provided, and Northwest Biotherapeutics Inc is yet to address the issue publicly.

Shares of Northwest Biotherapeutics Inc (NASDAQ: NWBO) declined to as low as $6.64 per share on August 24, 2015.